160 related articles for article (PubMed ID: 30153009)
1. Structure-Based Drug Design of Potent Pyrazole Derivatives against Rhinovirus Replication.
Da Costa L; Scheers E; Coluccia A; Casulli A; Roche M; Di Giorgio C; Neyts J; Terme T; Cirilli R; La Regina G; Silvestri R; Mirabelli C; Vanelle P
J Med Chem; 2018 Sep; 61(18):8402-8416. PubMed ID: 30153009
[TBL] [Abstract][Full Text] [Related]
2. A Novel Series of Highly Potent Small Molecule Inhibitors of Rhinovirus Replication.
Kim J; Jung YK; Kim C; Shin JS; Scheers E; Lee JY; Han SB; Lee CK; Neyts J; Ha JD; Jung YS
J Med Chem; 2017 Jul; 60(13):5472-5492. PubMed ID: 28581749
[TBL] [Abstract][Full Text] [Related]
3. Heterocyclic pharmacochemistry of new rhinovirus antiviral agents: A combined computational and experimental study.
Da Costa L; Scheers E; Coluccia A; Rosetti A; Roche M; Neyts J; Terme T; Cirilli R; Mirabelli C; Silvestri R; Vanelle P
Eur J Med Chem; 2017 Nov; 140():528-541. PubMed ID: 28987610
[TBL] [Abstract][Full Text] [Related]
4. Phenylpropenoids from Bupleurum fruticosum as Anti-Human Rhinovirus Species A Selective Capsid Binders.
Fois B; Bianco G; Sonar VP; Distinto S; Maccioni E; Meleddu R; Melis C; Marras L; Pompei R; Floris C; Caboni P; Cottiglia F
J Nat Prod; 2017 Oct; 80(10):2799-2806. PubMed ID: 29039946
[TBL] [Abstract][Full Text] [Related]
5. A novel benzonitrile analogue inhibits rhinovirus replication.
Lacroix C; Querol-Audí J; Roche M; Franco D; Froeyen M; Guerra P; Terme T; Vanelle P; Verdaguer N; Neyts J; Leyssen P
J Antimicrob Chemother; 2014 Oct; 69(10):2723-32. PubMed ID: 24948704
[TBL] [Abstract][Full Text] [Related]
6. Anionic Pulmonary Surfactant Lipid Treatment Inhibits Rhinovirus A Infection of the Human Airway Epithelium.
Numata M; Sajuthi S; Bochkov YA; Loeffler J; Everman J; Vladar EK; Cooney RA; Reinhardt RL; Liu AH; Seibold MA; Voelker DR
Viruses; 2023 Mar; 15(3):. PubMed ID: 36992456
[TBL] [Abstract][Full Text] [Related]
7. VP1 crystal structure-guided exploration and optimization of 4,5-dimethoxybenzene-based inhibitors of rhinovirus 14 infection.
Da Costa L; Roche M; Scheers E; Coluccia A; Neyts J; Terme T; Leyssen P; Silvestri R; Vanelle P
Eur J Med Chem; 2016 Jun; 115():453-62. PubMed ID: 27049678
[TBL] [Abstract][Full Text] [Related]
8. Cryo-EM structure of pleconaril-resistant rhinovirus-B5 complexed to the antiviral OBR-5-340 reveals unexpected binding site.
Wald J; Pasin M; Richter M; Walther C; Mathai N; Kirchmair J; Makarov VA; Goessweiner-Mohr N; Marlovits TC; Zanella I; Real-Hohn A; Verdaguer N; Blaas D; Schmidtke M
Proc Natl Acad Sci U S A; 2019 Sep; 116(38):19109-19115. PubMed ID: 31462495
[TBL] [Abstract][Full Text] [Related]
9. Susceptibilities of enterovirus D68, enterovirus 71, and rhinovirus 87 strains to various antiviral compounds.
Smee DF; Evans WJ; Nicolaou KC; Tarbet EB; Day CW
Antiviral Res; 2016 Jul; 131():61-5. PubMed ID: 27063860
[TBL] [Abstract][Full Text] [Related]
10. Rational design of highly potent broad-spectrum enterovirus inhibitors targeting the nonstructural protein 2C.
Bauer L; Manganaro R; Zonsics B; Hurdiss DL; Zwaagstra M; Donselaar T; Welter NGE; van Kleef RGDM; Lopez ML; Bevilacqua F; Raman T; Ferla S; Bassetto M; Neyts J; Strating JRPM; Westerink RHS; Brancale A; van Kuppeveld FJM
PLoS Biol; 2020 Nov; 18(11):e3000904. PubMed ID: 33156822
[TBL] [Abstract][Full Text] [Related]
11. Fragment-derived inhibitors of human N-myristoyltransferase block capsid assembly and replication of the common cold virus.
Mousnier A; Bell AS; Swieboda DP; Morales-Sanfrutos J; Pérez-Dorado I; Brannigan JA; Newman J; Ritzefeld M; Hutton JA; Guedán A; Asfor AS; Robinson SW; Hopkins-Navratilova I; Wilkinson AJ; Johnston SL; Leatherbarrow RJ; Tuthill TJ; Solari R; Tate EW
Nat Chem; 2018 Jun; 10(6):599-606. PubMed ID: 29760414
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and activity of piperazine-containing antirhinoviral agents and crystal structure of SDZ 880-061 bound to human rhinovirus 14.
Oren DA; Zhang A; Nesvadba H; Rosenwirth B; Arnold E
J Mol Biol; 1996 May; 259(1):120-34. PubMed ID: 8648640
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and in vitro evaluation of novel chroman-4-one, chroman, and 2H-chromene derivatives as human rhinovirus capsid-binding inhibitors.
Conti C; Proietti Monaco L; Desideri N
Bioorg Med Chem; 2011 Dec; 19(24):7357-64. PubMed ID: 22088306
[TBL] [Abstract][Full Text] [Related]
14. Anti-rhinovirus activity of 3-methylthio-5-aryl-4-isothiazolecarbonitrile derivatives.
Garozzo A; Cutrì CC; Castro A; Tempera G; Guerrera F; Sarvà MC; Geremia E
Antiviral Res; 2000 Mar; 45(3):199-210. PubMed ID: 10771083
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and anti-rhinovirus activity of novel 3-[2-(pyridinyl)vinyl]substituted -2H-chromenes and -4H-chromen-4-ones.
Conti C; Proietti Monaco L; Desideri N
Bioorg Med Chem; 2014 Feb; 22(3):1201-7. PubMed ID: 24360829
[TBL] [Abstract][Full Text] [Related]
16. Pyrazolopyrimidines: Potent Inhibitors Targeting the Capsid of Rhino- and Enteroviruses.
Makarov VA; Braun H; Richter M; Riabova OB; Kirchmair J; Kazakova ES; Seidel N; Wutzler P; Schmidtke M
ChemMedChem; 2015 Oct; 10(10):1629-34. PubMed ID: 26260222
[TBL] [Abstract][Full Text] [Related]
17. Modeling of the human rhinovirus C capsid suggests possible causes for antiviral drug resistance.
Basta HA; Ashraf S; Sgro JY; Bochkov YA; Gern JE; Palmenberg AC
Virology; 2014 Jan; 448():82-90. PubMed ID: 24314639
[TBL] [Abstract][Full Text] [Related]
18. Quantitative structure-activity relationship studies of [(biphenyloxy)propyl]isoxazole derivatives. Inhibitors of human rhinovirus 2 replication.
Kuz'min VE; Artemenko AG; Muratov EN; Volineckaya IL; Makarov VA; Riabova OB; Wutzler P; Schmidtke M
J Med Chem; 2007 Aug; 50(17):4205-13. PubMed ID: 17665898
[TBL] [Abstract][Full Text] [Related]
19. Screening of a Library of FDA-Approved Drugs Identifies Several Enterovirus Replication Inhibitors That Target Viral Protein 2C.
Ulferts R; de Boer SM; van der Linden L; Bauer L; Lyoo HR; Maté MJ; Lichière J; Canard B; Lelieveld D; Omta W; Egan D; Coutard B; van Kuppeveld FJ
Antimicrob Agents Chemother; 2016 May; 60(5):2627-38. PubMed ID: 26856848
[TBL] [Abstract][Full Text] [Related]
20. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 1. Michael acceptor structure-activity studies.
Dragovich PS; Webber SE; Babine RE; Fuhrman SA; Patick AK; Matthews DA; Lee CA; Reich SH; Prins TJ; Marakovits JT; Littlefield ES; Zhou R; Tikhe J; Ford CE; Wallace MB; Meador JW; Ferre RA; Brown EL; Binford SL; Harr JE; DeLisle DM; Worland ST
J Med Chem; 1998 Jul; 41(15):2806-18. PubMed ID: 9667970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
